Enteric Disease Testing Market Expected to Reach $5,323.60 million by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Enteric Disease Testing Market," The enteric disease testing market size was valued at $3,870.60 million in 2022 and is estimated to reach $5,323.60 million by 2032, growing at a CAGR of 3.3% from 2023 to 2032. 

Enteric diseases are a group of illnesses that affect the gastrointestinal tract, including the stomach and intestines. These diseases are typically caused by infection with bacteria, viruses, or parasites, and can result in symptoms such as diarrhea, vomiting, abdominal pain, and fever. Some common examples of enteric diseases include cholera, typhoid fever, norovirus, and E. coli infections. These diseases can be spread through contaminated food or water, or through contact with infected individuals or animals. Enteric diseases can be particularly dangerous for young children, the elderly, and people with weakened immune systems. 

Testing for enteric diseases can help to identify the cause of illness and guide appropriate treatment. Testing for enteric diseases can be done using molecular diagnostics and immunodiagnostics techniques. These techniques are helpful in the detection of C. difficile, campylobacteriosis, cholera, E. coli, H. pylori, salmonellosis, and shigellosis, rotavirus, norovirus, amebiasis, cryptosporidiosis and giardiasis.

The growth of the enteric disease testing market share is majorly driven by a rise in prevalence of typhoid fever, E. coli infection, amoebiasis, giardiasis, H. pylori infection, shigella and salmonella infection. For instance, according to the data of World Health Organization (WHO), data published in March 2022, researchers have estimated that each year there are 1.3 to 4.0 million cases of cholera, and 21,000 to 143,000 deaths worldwide due to cholera.

In addition, increase in awareness regarding diagnosis of enteric disease, high demand for enteric disease testing kit, and rise in technological advancement in enteric disease testing products drive the growth of the enteric disease testing market size. Furthermore, the surge in elderly population is further promoting the growth of the market for enteric disease testing because the aging population is more susceptible to enteric diseases such as cholera, E. Coli, H. Pylori, and cryptosporidiosis due to lower immunity. For instance, according to the Centers for Disease Control and Prevention (CDC), older adults (ages 75 years and older) are more at risk for cryptosporidiosis. Therefore, the rise in aging population is expected to boost the growth of the enteric disease testing market share during the forecast period. For instance, according to the United Nations Report on “World Population Ageing” published in December 2020, globally, there were 727 million people aged 65 years or above in 2020. 

Moreover, enteric disease testing market trends include rise in R&D investments, significant increase in capital income in developed countries, and surge in adoption of key strategies including product launch, collaboration, merger, funding, acquisition, agreement, adopted by key players. For instance, in January 2022, Meridian Bioscience Inc. announced that the Curian Campy assay has received U.S. Food and Drug Administration (FDA) clearance.  The Curian Campy assay is a rapid, qualitative fluorescent immunoassay for the detection of a Campylobacter-specific antigen including C. jejuni, C. coli, C. upsaliensis, and C. lari in human fecal specimens.  The assay was developed to be utilized on the Curian immunofluorescent testing platform.

On the basis of product type, the equipment segment is expected to witness the highest CAGR during the forecast period, owing to the short time period of testing, multiple samples can run together, higher accuracy, and high demand of automation for testing of enteric disease. 

On the basis of technique, the molecular diagnostics segment is expected to witness highest CAGR during the forecast period, owing to an increases demand of molecular diagnostics product, increase use of molecular diagnostics technique in research and increase in availability of molecular diagnostic technique equipment.

On the basis of disease type, the bacterial enteric disease segment is expected to witness the highest CAGR during the forecast period, owing to a rise in awareness regarding diagnosis of bacterial enteric diseases and rise in prevalence of bacterial enteric diseases globally.

On the basis of end user, the hospital laboratories segment is expected to witness the highest CAGR during the forecast period, owing to rise in diagnosis of enteric diseases in hospital laboratories and rise in awareness regarding routine body checkup in hospital laboratories. 

On the basis of region, North America generated maximum revenue in 2022. However, Asia-Pacific is expected to witness the highest CAGR, owing to increase in population, surge in healthcare expenditure, and rise in awareness related to testing of enteric disease. 

Key findings of the study

• On the basis of product type, the reagents and consumables segment held the largest share in the enteric disease testing industry in 2022.
• On the basis of technique, the immunodiagnostics segment dominated the market in 2022.
• On the basis of disease type, the bacterial enteric disease segment dominated the enteric disease testing industry in 2022. 
• On the basis of end user, in 2022, the hospital laboratories segment registered the highest growth in enteric disease testing market analysis.
• Region wise, Asia-Pacific is expected to witness the highest CAGR during the enteric disease testing market forecast.